All || Biopharma || Diagnostics and Life Science Tools || Medical Device || Healthcare IT || Healthcare Services || Exited


Fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China

IPO in May 2015 (HKSE: 1530)

Adaptive Biotechnologies

Diagnostics company developing immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems

IPO in June 2019 (NASDAQ: ADPT)

AK Medical

Largest domestic manufacturer of hip and knee artificial joints in China

IPO in Dec 2017 (HKSE: 1789)

ARMO Biosciences

Late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors

Acquired by Eli Lilly in May 2018

Cellular Research

Life science tools company developing a next-generation single cell preparation technology

Acquired by Becton Dickinson in August 2015


Diagnostics compaby based in Hong Kong and Silicon Valley developing proprietary plasma-based early cancer screening/detection utilizing next-generation sequencing

Acquired by GRAIL in May 2017


Diagnostics company developing and commercializing products for bacterial susceptibility testing for surveillance of hospital acquired infections

Acquired by Roche in August 2015


Healthcare company whose mission is to detect cancer early, when it can be cured

Acquired by Illumina in September 2020


Genetic information company with a mission to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people

IPO in February 2016 (NASDAQ: NVTA)


Life science tools company developing RNA sequencing technology by delivering the first panomic spatial sequencing platform

Acquired by 10X Genomics in October 2020


Medical device company with a novel suture delivery and tissue closure device for for patients with atrial fibrillation

Acquired by Atricure in August 2018


Biopharma company focused on developing an antibody-drug conjugate of cirmtuzumab, a ROR1 antibody

Acquired by Merck in November 2020

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.